Last reviewed · How we verify
NCT02758054
Patient Navigation for Lung Cancer Screening in an Urban Safety-Net System
Completed
NA
Last updated 6 April 2023
What this trial tests
NA trial testing Patient Navigation in Non-Small Cell Lung Carcinoma in 447 participants. Completed in 28 February 2020.
Timeline
16 June 2017
Primary endpoint
28 February 2020
28 February 2020
28 February 2020
Quick facts
| Lead sponsor | University of Texas Southwestern Medical Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | screening |
| Enrollment | 447 |
| Start date | 16 June 2017 |
| Primary completion | 28 February 2020 |
| Estimated completion | 28 February 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Patient Navigation
Conditions studied
- Non-Small Cell Lung Carcinoma — all drugs for Non-Small Cell Lung Carcinoma →
- Compliance Behavior — all drugs for Compliance Behavior →
- Prevention Harmful Effects — all drugs for Prevention Harmful Effects →
Sponsor
University of Texas Southwestern Medical Center
Who can join
Adults 55 to 74, any sex, with Non-Small Cell Lung Carcinoma or Compliance Behavior. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study proposes to evaluate a patient navigation intervention among a sample of 446 individuals referred for CT-based lung cancer screening in an urban safety-net setting.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Strategies to improve smoking cessation rates in primary care.
Lindson N, Pritchard G, Hong B, Fanshawe TR, et al · · 2021 · cited 45× · PMID 34693994 · DOI 10.1002/14651858.cd011556.pub2 -
Assessing Barriers and Facilitators to Lung Cancer Screening: Initial Findings from a Patient Navigation Intervention.
Lee SJC, Lee J, Zhu H, Chen PM, et al · · 2023 · cited 18× · PMID 37219548 · DOI 10.1089/pop.2023.0053 -
Patient navigation for lung cancer screening in an urban safety-net system: Protocol for a pragmatic randomized clinical trial.
Gerber DE, Hamann HA, Santini NO, Abbara S, et al · · 2017 · cited 18× · PMID 28689056 · DOI 10.1016/j.cct.2017.07.003 -
Tracking the Nonenrolled: Lung Cancer Screening Patterns Among Individuals not Accrued to a Clinical Trial.
Gerber DE, Hamann HA, Chavez C, Dorsey O, et al · · 2020 · cited 5× · PMID 32184050 · DOI 10.1016/j.cllc.2020.02.010
Verify or expand the search:
- PubMed search for NCT02758054
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Patient Navigation
Trials testing the same drug.
- NCT07332312 — A Culturally Informed Patient Navigation Program (CFPN) to Reduce Delays Between Diagnosis and Treatment in American Ind · NA · not yet recruiting
- NCT07176000 — Tailored Patient Navigation to Improve the Uptake of Lung Cancer Screening in Tribal Communities in Western Washington S · NA · not yet recruiting
- NCT07091617 — Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer · NA · recruiting
- NCT06995924 — Improving Uptake of Surveillance in Colorectal Cancer Survivors Through Navigation and Web Education · NA · recruiting
- NCT07052630 — Patient Navigation and the Planning Advance Care Together Website to Improve Goals of Care Conversations in Hematopoieti · NA · recruiting
Other recruiting trials for Non-Small Cell Lung Carcinoma
Currently open trials in the same condition.
- NCT07144280 — A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previ · Phase 3 · recruiting
- NCT06222489 — Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT · Phase 2 · recruiting
- NCT05358249 — Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation · Phase 1, PHASE2 · active not recruiting
- NCT04585750 — The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) · Phase 1, PHASE2 · recruiting
- NCT03731585 — Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small Cell Lung · NA · active not recruiting
Other University of Texas Southwestern Medical Center trials
Trials by the same sponsor.
- NCT03849963 — Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain · recruiting
- NCT06917183 — Developing Strategies for Implementation and Use of the Operating Room Black Box (ORBB) · NA · not yet recruiting
- NCT05145309 — Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans · Phase 2 · not yet recruiting
- NCT06552000 — Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer · NA · not yet recruiting
- NCT07387666 — Imaging Acetadote Metabolism in Glioblastoma · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT02758054 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Texas Southwestern Medical Center
- Last refreshed: 6 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02758054.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing